Brookfield Asset Management Ltd. has withdrawn its plan to acquire Grifols SA, ending several months of negotiations for the Spanish blood-plasma company. The offer was valued at €6.45 billion, or approximately $6.8 billion.
The decision to walk away follows disagreements on the company's valuation, as indicated by Grifols' board previously issuing an unfavorable opinion on Brookfield's bid. This marks the termination of a significant potential acquisition.
The exit from this bid means Brookfield will not proceed with its planned expansion into the drugmaker sector through Grifols. This development concludes a period of uncertainty regarding the potential takeover.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.